Avivomed, Inc., a privately held, development stage, medical device company, announced the completion of a Series A Preferred Stock financing of $32 million. A world-class syndicate of experienced medical device investors participated in the financing. The proceeds of the Series A financing will provide the resources to enable the company to pursue the development and commercialization of innovative neuromodulation technology platforms to treat large patient populations suffering from chronic diseases.